Appendix Table C41Trial description: intranasal corticosteroid versus leukotriene receptor antagonist

Author, YearLocation/Site(s)Enrollment/Treatment DurationFunding/Author Industry DisclosuresNInclusion CriteriaExclusion CriteriaaRescue Medication UseObjective DiagnosisRun-in PeriodPollen Counts MeasuredPatient BlindingAssessor Blinding
Lu, 2009 (Trial 1)N.America
Multiple
April 1998
2 weeks
Industry/Industry285Minimum SAR severity and durationNo
Martin, 2006N.America
Multiple
December 2001
2 weeks
Industry/Industry736Minimum SAR severity and durationSAR meds/NR
Other meds
Pregnancy
Deformities
No
Nathan, 2005N.America
Multiple
4 weeksIndustry/Industry573Minimum SAR severity and durationSAR meds/+
Pregnancy
Infection
Deformities
Yes
Pullerits, 2002Europe03/1999
8 weeks
Industry/29Minimum SAR durationOther meds
Pregnancy
Infection
Yes
Ratner, 2003N.America
Multiple
December 2001
2.1 weeks
Industry/Industry705Minimum SAR severity and durationSAR meds
Other meds
Pregnancy
Deformities
No

N = patients randomized to comparator groups of interest; SAR = seasonal allergic rhinitis.

a

+, -, or NR indicates whether FDA-recommended washout periods were required (+), were not required (-), or were not reported (NR) for restricted SAR medications prior to trial entry.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.